Clinical studies overview Search menu
  1. Home
  2. Clinical studies overview
  3. SGNCEA5C-001

SGNCEA5C-001

A Phase 1 Open-Label Study of SGN CEACAM5C in Adults With Advanced Solid Tumors.

  • NKI code: M23CEA
  • Code firm: SGNCEA5C-001
  • Code clinicaltrials.gov: NCT06131840

Principal investigator

Dr. N. Steeghs

Medication

Tusamitamab (PF-08046050/SGN-CEACAM5C) is a humanized IgG1 anti-CEACAM5 monoclonal antibody (mAb) conjugated to the topoisomerase I inhibitor – AMDCPT (aminomethyl-10,11-methylenedioxycamptothecin).

Summary

This study will look at the effect, safety and possible side effects of the drug PF-08046050/SGN-CEACAM5C. SGN-CEACAM5C is a type of drug called an antibody-drug conjugate (ADC).

The research consists of 3 parts. In parts A and B, the correct dosage is investigated. In Part C, this information is used to investigate how well the medicine works in certain types of solid tumours. The side effects are also looked at in that part.

Read more on clinicaltrials.gov.

Notes

  • Escalation section for PDAC – open
  • Escalation section for CRC – closed
onload

Disclaimer

This translation was generated automatically based on information in Dutch. It has not been reviewed by a medical specialist. The purpose of this translation is to make our information accessible to non-Dutch speakers. However, this information should not be considered a substitute for medical advice from your treating physician. The Netherlands Cancer Institute cannot guarantee the accuracy of this translation. For medical questions or advice, please consult your physician.

This website uses cookies

The NKI Centre for Early Clinical Studies places functional cookies and analytical cookies with very little or no privacy impact, unless you give permission for other cookies (as shown below). More information can be found in our cookie statement at the bottom of this page.

Functional and analytical
[1]
  • A working website
    By placing this cookie, we can offer you a functional website and we as an organization receive anonymized website statistics.
Media
[1]
  • YouTube
    This allows you to watch the videos on our website

Cookie Information

Accept cookies!